Every material Form 8-K Caris Life Sciences, Inc. has filed with the SEC since August 05, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Caris Life Sciences reported third quarter 2026 revenue of $275.4 million, up 27% from a year earlier, and raised its full-year 2026 revenue forecast to $1.04 billion to $1.05 billion. Net income fell to $15.3 million from $24.3 million, and operating cash flow was negative, so shareholders get faster sales growth alongside lower profit and cash generation.
Q3 2026 total revenue was $275.4 million, up from $216.8 million in Q3 2025.
Net income was $15.3 million, down from $24.3 million; basic and diluted EPS were $0.05 versus $0.09 and $0.08.
Full-year 2026 revenue guidance raised to $1.04 billion to $1.05 billion, growth of 28% to 29%.
Net cash used in operating activities was $22.2 million; free cash flow was $(39.7) million.
Caris Life Sciences said that starting September 14, 2026, its representatives will use an investor presentation in meetings with current and potential investors at the Morgan Stanley 24th Annual Global Healthcare Conference and at other investor events. The company will post the presentation on its investor relations website. The filing contains no financial results, guidance, or new business developments, so it offers no direct read on company performance.
Presentation to be used starting September 14, 2026 at the Morgan Stanley 24th Annual Global Healthcare Conference
Company will post the Investor Presentation at investor.carislifesciences.com
Information is furnished under Item 7.01 and is not deemed filed under Section 18 of the Exchange Act
Caris Life Sciences reported second-quarter 2026 revenue of $263.7 million, up 45% from $181.4 million a year earlier, and narrowed its net loss to $0.6 million from $71.8 million. The company raised its full-year 2026 revenue guidance to $1.03 billion to $1.04 billion, which it says represents growth of 27% to 28%, giving shareholders a higher revenue outlook.
Q2 2026 total revenue was $263.7 million, up $82.3 million, or 45%, from the prior year period.
Net loss was $0.6 million, or $0.00 per share, compared with a net loss of $71.8 million, or $7.97 per share, a year earlier.
Adjusted EBITDA was $55.7 million, and free cash flow was $6.4 million for the quarter.
Full-year 2026 revenue guidance was raised to $1.03 billion to $1.04 billion; about $82.1 million remains under the existing share repurchase authorization.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Caris Life Sciences, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →